Compare GBCI & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBCI | SRRK |
|---|---|---|
| Founded | 1955 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.8B |
| IPO Year | 1996 | 2018 |
| Metric | GBCI | SRRK |
|---|---|---|
| Price | $48.82 | $52.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $54.00 | ★ $56.17 |
| AVG Volume (30 Days) | ★ 1.2M | 985.7K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | ★ 18.45 | N/A |
| EPS | ★ 1.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.52 | N/A |
| Revenue Next Year | $8.46 | $534.24 |
| P/E Ratio | $36.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.90 | $27.07 |
| 52 Week High | $54.58 | $58.49 |
| Indicator | GBCI | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 48.67 | 44.65 |
| Support Level | $49.98 | $45.83 |
| Resistance Level | $50.40 | $51.55 |
| Average True Range (ATR) | 1.14 | 2.10 |
| MACD | -0.14 | -0.35 |
| Stochastic Oscillator | 32.60 | 33.55 |
Glacier Bancorp Inc is a regional bank holding company providing commercial banking services through its wholly owned bank subsidiary, Glacier Bank. The group provides a full range of banking services to individuals, small to medium-sized businesses, community organizations, and public entities from several locations in Montana, Idaho, Utah, Washington, Wyoming, Colorado, Arizona, Nevada, and Texas. It offers various banking products and services, including: retail banking, business banking, real estate, commercial, agriculture, and consumer loans; and mortgage origination and loan servicing services, among others.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.